Clostridium spp. as Next Generation Probiotics
Along with over a decade of extensive experience in next-generation probiotics (NGPs), Creative Biolabs has won a great reputation among our worldwide customers for accomplishing numerous challenging projects. The Clostridia genus consists of a large and heterogeneous group of gram-positive, spore-forming bacteria that could be used as probiotic agents for the therapy of different diseases.
Introduction of Clostridium spp.
The genus Clostridium is a diverse group of rod-shaped bacteria characterized by a gram-positive cell wall structure, fermentative anaerobic metabolism, and the formation of endospores. The genus Clostridium presently comprises a large collection of more than 100 physiologically diverse Gram-positive bacterial species. The Clostridium spp. includes common free-living bacteria and important pathogens. They are normal in the soil, aquatic sediments, and intestinal tract of both animals and humans. Although they have a consequence of pathogenic representatives such as C. botulinum or C. tetani, most of the members are nonpathogenic. Nonpathogenic species include the following. These species of Clostridium are used in acetone, butanol, and isopropanol fermentation.
Probiotic treatment is an effective treatment option, and the most advanced probiotic for improving IBD and preventing CDI investigation is Clostridium. Among them, C. butyricum MIYAIRI 588 (CBM588) is a specific phenotype of the strain C. butyricum, which are putative anti-inflammatory microbes. CBM588 produces short-chain fatty acids (SCFAs), which have major therapeutic effects. Besides, C. butyricum CBM588 regulates IL-10 production by intestinal macrophages in inflamed mucosa and prevents the development of colitis. Therefore, CBM588 may have the potential as an immunomodulatory probiotic for both maintenance and induction of remission in IBD and CDI.
Viable bacterial preparations such as probiotics have been shown to control metabolic function and improve various symptoms and have been used for the treatment of conditions such as NAFLD. C. butyricum CBM588 may have the novel potential for decreasing lipid accumulation in the liver and improving high-fat diet-induced NAFLD in rats. The availability of CBM588 for NAFLD therapy should stimulate further preclinical work to validate findings that would encourage the initiation of a future clinical study.
Clostridium for Cancer Therapy
Clostridium-based cancer therapy is one of the most novel and promising cancer treatments currently under investigation. Several Clostridium species have been tested as anticancer agents. One of the major advantages of Clostridium in the treatment of cancer is the ability to specifically target tumors. This Clostridium-based system makes them ideal delivery vehicles for anticancer drugs because of its lack of toxicity and its highly selective growth in tumors.
Services for Clostridium spp. Research
An in-depth analysis of the presence and content of specific Clostridium species will help us understand how these bacteria affect disease progression, treatment, and recovery. Clostridium species have valuable properties in the field of probiotics.
Various strategies for the use of Clostridium are currently being investigated and represent a new field of emerging therapies for different diseases. Creative Biolabs is recognized as an expert in supporting a wide range of research projects. If you are interested in our Clostridium spp. research services, please feel free to contact us for more detailed information.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
